Prevalence of Human Cytomegalovirus Infection in Iranian Prostate Cancer Patients

Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 72

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJMM-17-4_001

تاریخ نمایه سازی: 13 آبان 1402

Abstract:

Background and Aim: Human cytomegalovirus (HCMV) has the potential for oncogenicity and has been associated with many malignancies, including prostate cancer. This study aimed to investigate the genomic prevalence of HCMV in prostate cancer tumors. Materials and Methods: In this case-control study, ۳۱ patients with prostate cancer were enrolled along with ۳۱ patients with benign prostate cancer as the control group. The presence of the HCMV genome was assessed using real-time polymerase chain reaction (PCR). The nested-PCR test was also used to detect the UL۵۵ virus gene. Purified PCR products were sequenced using the Sanger method by a commercial service provider (Pishgam Co.), and the results were analized using Chromase software. Results: The overall mean (±SD) prostate-specific antigen (PSA) value was ۹ (±۷.۸) ng/Ml in patients with different stages of prostate cancer, and ۹ (±۳) ng/Ml in the control group (P=۰.۰۹). The prevalence of HCMV DNA was ۱۹.۳% (n=۶) in the case group, and ۶.۵% (n=۲) in the control group (P=۰.۱۴). The highest prevalence was observed in stage IIA (۳۳.۳%), followed by stages III (۲۵%), and IIB (۱۲.۵%) (P=۰.۰۱۶). There were close phylogenetic relationships between Iranian HCMV isolates and several reference genotypes – the closest genetic relationship was observed with the KR ۵۳۴۲۰۷ genotype. Conclusion: The prevalence of HCMV in the prostate cancer group was markedly higher than that of the control group, although this difference was not significant. However, the higher prevalence of HCMV in prostate cancer patients compared to the control group is indicative of the possible role of HCMV in the development of prostate cancer.

Authors

Ehsan Alborzi

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Ahmad Tavakoli

Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

Seyed Jalal Kiani

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Saied Ghorbani

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Davod Javanmard

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

Milad Sabaei

Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

Maryam Fatemipour

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Seyed Hamidreza Monavari

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Demaria S, Pikarsky E, Karin M, Coussens LM, Chen Y-C, ...
  • Moghoofei M, Keshavarz M, Ghorbani S, Babaei F, Nahand JS, ...
  • Farahmand M, Monavari SH, Shoja Z, Ghaffari H, Tavakoli M, ...
  • Salehi-Vaziri M, Sadeghi F, Bokharaei-Salim F, Younesi S, Alinaghi S, ...
  • Fateh A, Aghasadeghi M, Siadat SD, Vaziri F, Sadeghi F, ...
  • Sadeghi F, Bokharaei‐Salim F, Salehi‐Vaziri M, Monavari SH, Alavian SM, ...
  • Salehi-Vaziri M, Sadeghi F, Alamsi-Hashiani A, Haeri H, Monavari SH, ...
  • Sadeghi F, Salehi‐Vaziri M, Alizadeh A, Ghodsi SM, Bokharaei‐Salim F, ...
  • Sadeghi F, Salehi-Vaziri M, Ghodsi SM, Alizadeh A, Bokharaei-Salim F, ...
  • Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. ...
  • Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. ...
  • Yang YM, Kim SY, Seki E, editors. Inflammation and liver ...
  • Zhang J, Li X, Hu J, Cao P, Yan Q, ...
  • https://doi.org/۱۰.۱۱۸۶/s۱۲۹۸۵-۰۲۰-۰۱۳۰۸-yAthanasiou E, Gargalionis AN, Boufidou F, Tsakris A. The Association ...
  • Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. ...
  • Taher C, de Boniface J, Mohammad A-A, Religa P, Hartman ...
  • Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, ...
  • Nauclér CS, Geisler J, Vetvik K. The emerging role of ...
  • Fode M. Introduction for sexuality after prostate cancer. Int J ...
  • Auchus RJ, Sharifi N. Sex Hormones and Prostate Cancer. Annu ...
  • Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL, Committee ...
  • Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, ...
  • Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma ...
  • Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, ...
  • Plotkin SA, Wang D, Oualim A, Diamond DJ, Kotton CN, ...
  • Archer M, Dogra N, Kyprianou N. Inflammation as a driver ...
  • Bai B, Wang X, Chen E, Zhu H. Human cytomegalovirus ...
  • Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, ...
  • MEHRABANI KS, Ghane M, Ameli M. Prevalence of Cytomegalovirus Infection ...
  • Nakhaie M, Charostad J, Ghaderi-Zefrehi H, Arabzadeh SAM, Pourhosseini F, ...
  • Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, ...
  • Sutcliffe S, Till C, Gaydos CA, Jenkins FJ, Goodman PJ, ...
  • Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. ...
  • Bergh J, Marklund I, Gustavsson C, Wiklund F, Grönberg H, ...
  • Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo ...
  • Li Y, Huang M, Zhang Y, Chen J, Xu H, ...
  • Mun Y, Paik I, Shin S-J, Kwak T-Y, Chang H. ...
  • Wang B, Gu W, Wan F, Wei Y, Xiao W, ...
  • نمایش کامل مراجع